ETNB News and Press, 89bio Inc. From 07/07/22

Target Hospitality ( TH ) +22% e xpanded partnership with Leading National Nonprofit Supporting Critical Humanitarian Aid Solutions. Annovis Bio ( ANVS ) +17% wins FDA nod to begin late-stage study for Parkinson's candidate. Grove Collaborative Holdings...

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced ...

Agile Therapeutics ( AGRX ) -16% . Bed Bath & Beyond ( BBBY ) -13% on Q1 earnings release . Barnes & Noble Education ( BNED ) -15% on Q4 earnings release . Himax Technologies ( HIMX ) -12% . AeroVironment ( AVAV ) -...

89bio (ETNB) is down 4.8% after-hours after the firm has priced its previously announced underwritten public offering of 18.68M shares of its common stock and accompanying warrants to purchase up to 9.34M shares of common stock at a combined public offering price of $3.55 and, in li...

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced ...

Gainers: Tactile Systems Technology (TCMD) +4.9%. Roth CH Acquisition (ROCC) +4.9%. Hertz Global Holdings (HTZ) +4.8%. WM Technology (MAPS) +4.7%. LendingTree (TREE) +4%. Losers: Icosavax (ICVX) -22.0%. AeroVironment (AVAV) -10.1%. Playa Hotels & Resorts (PLYA) -3.0%. 89bio (ETN...

89bio (NASDAQ:ETNB) shares dropped over 5% during Tuesday extended trading after the biopharmaceutical company proposed an underwritten public offering of $75M of shares of its common stock, pre-funded warrants and accompanying warrants to purchase shares of its common stock. Net pr...

A phase 2 trial of 89bio's (NASDAQ:ETNB) pegozafermin met its primary endpoint as a treatment of severe hypertriglyceridemia. Patients on pegozafermin saw clinically meaningful and significant reductions in triglycerides from baseline through week 8 across all doses. The highest dose saw the ...

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced t...

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed ...